Abstract
Monoclonal antibodies (mAbs) comprise the majority of protein candidates currently in clinical development because of their versatility as therapeutic agents. While traditionally associated with the biotechnology industry, mAb therapeutics are now being developed and marketed by most major pharmaceutical firms. A total of 21 products are approved in the US, with additional products marketed outside the US, and over 200 mAb candidates are currently undergoing clinical study. Benchmark data for mAb therapeutics, such as clinical development and US Food and Drug Administration approval times, approval success rates, and clinical phase transition probabilities, are critical for strategic planning purposes. Trends in these benchmarks for various types of mAbs, with an emphasis on those studied as anticancer and immunological therapeutics, are discussed.
Keywords: Monoclonal antibodies, success rates, clinical study, Food and Drug Administration, marketing approval, benchmarks
Current Pharmaceutical Biotechnology
Title: Monoclonal Antibodies as Innovative Therapeutics
Volume: 9 Issue: 6
Author(s): Janice M. Reichert
Affiliation:
Keywords: Monoclonal antibodies, success rates, clinical study, Food and Drug Administration, marketing approval, benchmarks
Abstract: Monoclonal antibodies (mAbs) comprise the majority of protein candidates currently in clinical development because of their versatility as therapeutic agents. While traditionally associated with the biotechnology industry, mAb therapeutics are now being developed and marketed by most major pharmaceutical firms. A total of 21 products are approved in the US, with additional products marketed outside the US, and over 200 mAb candidates are currently undergoing clinical study. Benchmark data for mAb therapeutics, such as clinical development and US Food and Drug Administration approval times, approval success rates, and clinical phase transition probabilities, are critical for strategic planning purposes. Trends in these benchmarks for various types of mAbs, with an emphasis on those studied as anticancer and immunological therapeutics, are discussed.
Export Options
About this article
Cite this article as:
Reichert M. Janice, Monoclonal Antibodies as Innovative Therapeutics, Current Pharmaceutical Biotechnology 2008; 9 (6) . https://dx.doi.org/10.2174/138920108786786358
DOI https://dx.doi.org/10.2174/138920108786786358 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Curcumin: A Natural Pan-HDAC Inhibitor in Cancer
Current Pharmaceutical Design Peptido-Targeting of the Mitochondrial Transition Pore Complex for Therapeutic Apoptosis Induction
Current Pharmaceutical Design Prediction and Monitoring of Therapeutic Response by Molecular Imaging
Current Medical Imaging Modulating Mesenchymal Stromal Cell Function with Cholesterol Synthesis Inhibitors
Current Medicinal Chemistry Chemosensitization by Antisense Oligonucleotides Targeting MDM2
Current Cancer Drug Targets Quantum Molecular Dynamics, Topological, Group Theoretical and Graph Theoretical Studies of Protein-Protein Interactions
Current Topics in Medicinal Chemistry Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets Severe Hypoglycemia Due to Possible Interaction Between Glibenclamide and Sorafenib in a Patient with Hepatocellular Carcinoma
Current Drug Safety Omega – 3 Fatty Acids as Pharmacotherapeutics in Psoriasis: Current Status and Scope of Nanomedicine in its Effective Delivery
Current Drug Targets Non-Genotoxic p53-Activators and their Significance as Antitumor Therapy of Future
Current Medicinal Chemistry Prospects and Limitations of T Cell Receptor Gene Therapy
Current Gene Therapy Second-Generation Tyrosine Kinase Inhibitors as First-Line Treatment Strategy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients
Current Cancer Drug Targets Telomerase Inhibitors as Anticancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Chemical and Pharmacological Significance of Natural Guanidines from Marine Invertebrates
Mini-Reviews in Medicinal Chemistry Targeting Protein Degradation in Cancer Treatment
Current Chemical Biology The Potential and Limitations of p38MAPK as a Drug Target for the Treatment of Hematological Malignancies
Current Drug Targets Immunoproteasome-Selective Inhibitors: A Promising Strategy to Treat Hematologic Malignancies, Autoimmune and Inflammatory Diseases
Current Medicinal Chemistry Lymphatics and Inflammation
Current Medicinal Chemistry HIV-1 Latency and Eradication: Past, Present and Future
Current HIV Research